Kodiak Sciences (NYSE:KOD) Sets New 12-Month High at $23.29

Kodiak Sciences Inc. (NYSE:KOD) shares reached a new 52-week high on Monday . The stock traded as high as $23.29 and last traded at $22.93, with a volume of 6496 shares. The stock had previously closed at $21.90.

Several equities research analysts recently weighed in on KOD shares. Zacks Investment Research cut shares of Kodiak Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Chardan Capital upped their price objective on Kodiak Sciences from $22.50 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th.

The business’s 50-day simple moving average is $18.25 and its two-hundred day simple moving average is $12.98.

Kodiak Sciences (NYSE:KOD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02).

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of Kodiak Sciences by 179.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,476 shares of the company’s stock worth $73,000 after buying an additional 4,161 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $73,000. Hillsdale Investment Management Inc. bought a new position in shares of Kodiak Sciences in the 2nd quarter worth $99,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Kodiak Sciences in the 2nd quarter worth $122,000. Finally, California Public Employees Retirement System bought a new position in shares of Kodiak Sciences in the 3rd quarter worth $163,000.

About Kodiak Sciences (NYSE:KOD)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Further Reading: How to find the components of the quick ratio

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.